Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06668519
Recruiting Observational

Magnetoencephalography in Children

NCT06668519 · tracked via the Priya Life Science China tracker
Sponsor
Children's Hospital of Fudan University
Phase
Observational
Started
2024-09-25
Last updated
2026-03-25

Condition(s) studied

EpilepsyIntracranial TumorsCerebrovascular DiseaseAutismADHD - Attention Deficit Disorder With HyperactivityNeuropsychiatric DisordersTic Disorder, ChildhoodMental RetardationDevelopmental Disabilities

Investigational drug(s) / intervention(s)

Magnetoencephalography

Magnetoencephalography: Magnetoencephalography

Study summary

This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.

Eligibility

Sex
ALL
Min age
1 Month
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: 1. aged 1 month-18 years old (date of investigate minus date of birth) 2. epilepsy 3. intracranial tumors 4. cerebrovascular diseases 5. autism 6. mental retardation 7. ADHD 8. tic disorder 9. neuropsychiatric disorders Exclusion Criteria: 1.Unable to cooperate with the exam of MEG

Primary outcome measure(s)

  • Difference in magnetoencephalography (MEG) signal between children with neurodevelopmental diseases and healthy children — 3 years
    Acquisition of magnetoencephalography (MEG) signals based on Inclusion Criteria

Trial sites (1)

FacilityCityRegionStatus
Children's Hospital of Fudan University Shanghai China Recruiting

More Children's Hospital of Fudan University trials in China

Clinical Implementation of the Group Standard for Enteral Feeding Care in Critically Ill Children Starting soon
PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection Recruiting
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases Starting soon
Development of an Early Warning Model for Intensive Care Unit-Acquired Weakness in Mechanically Ventilated Children Enrolling by invitation
Interactive Massage Intervention in Toddlers With Autism Spectrum Disorder Recruiting

Other trials for the same condition

Interactive Massage Intervention in Toddlers With Autism Spectrum Disorder Recruiting
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease Recruiting
(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction Starting soon
Effects of Lactic Acid Bacteria in Patients With Attention-Deficit/Hyperactivity Disorder Enrolling by invitation
Parent-Mediated Social Cognition Intervention for Young Children With Autism Spectrum Disorder Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06668519 on ClinicalTrials.gov ↗ ← All trials in China